Navigation Links
ThromboGenics NV Announces Business Update and Half Year Results 2009
Date:8/27/2009

Roche for the novel anti-cancer antibody TB-403 is also going well, as evidenced by the success fee that we received from them earlier in the year."

"ThromboGenics' business has never been so well placed. We have a clear strategy, an exciting lead product in microplasmin and two further assets in TB-402 and TB-403 which will provide us with further opportunities to deliver value for our shareholders."

    Financial Update

    - ThromboGenics achieved revenues of EUR3.6 million in the
      first half of 2009, nearly all of which came from a success fee from
      Roche, our partner for TB-403. R&D expenses were EUR8.8 million during
      this six month period. In addition EUR5.7 million of expenses related
      to the microplasmin Phase III clinical program (called MIVI TRUST) have
      been capitalized. General and administrative costs in the first half
      increased from EUR1.2 million to EUR1.7 million due to higher one-time
      legal costs, in part due to the merger of ThromboGenics NV and
      ThromboGenics Ltd. In the first half, ThromboGenics made a net loss of
      EUR4.7 million.

    - As of June 30, 2009, ThromboGenics had EUR52.6 million in
      cash and cash equivalents. This compares to EUR40.4 million on June 30,
      2008 and EUR58.9 million on December 31, 2008. The cash figure at the
      end of June includes the EUR3.1 million that ThromboGenics received in
      May as a result of the exercise of warrants. The Company's cash
      resources are expected to allow ThromboGenics to execute its current
      operational plans for approximately the next two years.


    Business Highlights
    Clinical Highlights

Microplasmin - Back of the Eye Disease: Phase III clinical program to evaluate non-surgical treatment of patients with vitreomacular adhesion.

    - Phase III program continues to progress well, with
      recruitment on track


'/>"/>
SOURCE ThromboGenics NV
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. ThromboGenics NV: Business Update
2. ThromboGenics Announces Business Update and 2008 Full Year Results
3. ThromboGenics and BioInvent Start Phase II Trial of TB-402, a Novel, Long Acting Anticoagulant for Deep Vein Thrombosis (DVT) Prophylaxis
4. ThromboGenics N.V.: Business Update
5. ThromboGenics Announces Half Year Results 2008
6. ThromboGenics Appoints Dr. Patrik De Haes as Chief Executive Officer
7. ThromboGenics Announces Private Investors Acquire 8% Stake in the Company
8. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
9. ThromboGenics N.V. - Business Update
10. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
11. ThromboGenics Announces 2007 Full Year Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... Dec. 22, 2014  ( www.competitivehealth.com ) — Competitive ... medical bill review and advocacy service, has signed an ... WellCard Savings discount health services marketplace. 63% ... more than they expected to pay. As part of ... costs, WellCard Savings is pleased to offer medical bill ...
(Date:12/22/2014)... 22, 2014 Fertility Associates of Memphis ... Bank USA , a network of more than 20 ... partnership, patients have fast access to a national pool ... IVF . Fertility Associates of Memphis is the only ... treatment option. , Dr. William Kutteh , director ...
(Date:12/19/2014)... BioPlus Specialty Pharmacy (BioPlus), one ... of Nick Maroulis, Pharm.D. to the newly created position ... In this position, Dr. Maroulis will continue to manage ... of our multi-site pharmacies as the company expands. Dr. ... that time he has served in many different capacities ...
(Date:12/19/2014)... Dec. 19, 2014 Bina Technologies, Inc. (Bina, ... that they have been acquired by Roche (SIX: RO, ... privately held company that provides a big data platform ... (NGS) data for the academic and translational research markets. ... and will continue to focus on development of their ...
Breaking Biology Technology:WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 3BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2Bina Technologies is acquired by Roche. 2Bina Technologies is acquired by Roche. 3
... , SAN DIEGO, Aug. 6 SEQUENOM, Inc. ... ended June 30, 2009. , , (Logo: http://www.newscom.com/cgi-bin/prnh/20040415/SQNMLOGO ) , ... Total revenue for the second quarter of 2009 was $9.2 million, ... the comparable period last year was primarily due to softness in capital expenditure ...
... ... Launch Of Its New And Improved Website. The New Site Provides Users With A ... Functionality And Navigation. The Site Also Offers An Expanded Service Description For Each Of ... ...
... , , LOS ANGELES, Aug. 6 ... an 82 year-old Chinese female immigrant who suffered Stevens-Johnson Syndrome/Toxic Epidermal ... Defendant, an osteopathic physician and registered pharmacist, prescribed it to her ... did not have gout. The doctor claimed that she told ...
Cached Biology Technology:SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights 2SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights 3SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights 4SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights 5SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights 6SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights 7SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights 8SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights 9SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights 10One of the Nation's Leading Analytical Testing Laboratories is Now Easier to Access -- Pace Analytical Launches New Web Site to Showcase Its Three Business Divisions 2The Law Offices of Brian D. Witzer Wins 6+ Million Dollar Verdict 2
(Date:12/19/2014)... --  LaunchKey , the first decentralized mobile authentication and ... Things era, today announced the close of $3 million ... by Metamorphic Ventures with participation from ENIAC Ventures, Crosslink ... LaunchKey has raised $4 million to date, and will ... bring LaunchKey to market in 2015. LaunchKey ...
(Date:12/17/2014)... , Dec. 16, 2014 Research and ... the addition of the "Global Chemical Sensor ... http://photos.prnewswire.com/prnh/20130307/600769 ... the increasing demand for medical sensors in biomedical ... data for quick and correct diagnosis during surgical ...
(Date:12/11/2014)... 2014  That blood pressure plays a role in human ... the medical term for high blood pressure – was first ... inflatable cuff that,s used in measuring blood pressure was invented ... new about hypertension, its triggers and its effects. In fact, ... and the best ways to treat it. For ...
Breaking Biology News(10 mins):LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4
... FRANCISCO - Scientists from the Department of Energy,s Pacific ... energy-related research at the 2012 American Geophysical Union Fall ... 7 at the Moscone Convention Center in San Francisco. ... measuring the resources needed to grow algae for biofuel ...
... The William R. Kenan, Jr. Charitable Trust has awarded ... $1 million to support the institute,s education outreach programs ... single gift to date in support of Scripps Florida,s ... Kenan Trust support, the new four-year grant will run ...
... study may help scientists produce better climate-resistant corn and other ... that we are what we eat. Kansas State University ... used to study and prioritize the genes in humans, it ... plants. These genes control quantitate traits in plants, such as ...
Cached Biology News:Sunshine, biofuel and the tides, oh my! 2Sunshine, biofuel and the tides, oh my! 3Study finds prioritizing rather than canvassing entire plant genome may lead to improved crops 2Study finds prioritizing rather than canvassing entire plant genome may lead to improved crops 3
Human Cell Line Slides...
... Each Signet Level 2 Detection ... the avidin-biotin chemical bonding principle and ... to provide sensitivity, specificity and reliablility. ... immunostaining in both manual and automated ...
Mouse monoclonal [3576] to Yellow Fever Virus ( Abpromise for all tested applications). Antigen: Tissue / cell preparation...
... Level 2 Detection System combines the ... bonding principle and Signets unique formulation ... specificity and reliablility. Signet reagents will ... manual and automated protocols. ,Signets ...
Biology Products: